Especifique uma ação ou criptomoeda na barra de pesquisa para obter um resumo
ExpreS2ion Biotech Holding AB
EXPRS2ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2ion Biotechnologies ApS, researches and develops preventive and therapeutic vaccine products in the Nordics and internationally. The company's lead asset is ES2B-C001, a therapeutic vaccine for breast cancer that targets the human epidermal growth factor receptor 2 receptor. It is also developing ES2B-I002, a cytomegalovirus vaccine candidate to treat infectious diseases. In addition, the company out licenses its ExpreS2 platform to research institutes and pharmaceutical companies. Further, it sells ExpreS2 test kits and reagents for research purposes or diagnostic applications. The company has collaboration agreement with University of Oxford for the development of vaccine for malaria; and Evaxion Biotech A/S for development of cytomegalovirus vaccine, as well as partnership agreement with Copenhagen University to develop vaccine for Influenza. The company operates an online store. ExpreS2ion Biotech Holding AB (publ) was incorporated in 2015 is based in Helsingborg, Sweden. Address: ROennowsgatan 8C, Helsingborg, Sweden, 252 25
Analytics
Preço Alvo de Wall Street
1 102.75 SEKRácio P/E
–Rendimento de dividendos
–Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Figuras chave EXPRS2
Análise de Dividendos EXPRS2
Crescimento de dividendos em 5 anos
–Crescimento contínuo
–Taxa de pagamento em média de 5 anos
–Histórico de Dividendos EXPRS2
Avaliação de ações EXPRS2
Relatório EXPRS2
Acompanhe as principais métricas de cada ação em um só lugar, sem complicações
Inscreva-se no premiumResultados | 2019 | Dinâmica |